Decision Resources is the premier provider of analysis and data on the significant issues facing the biopharmaceutical industry.
Amgen’s evolocumab (AMG-145) is set to become the clinical gold-standard among statin add-on therapies used to treat patients with dyslipidemia... Learn More
Recorded live on October 22, 2014... Learn More
View Webinar schedule and archive
See which reports have been searched on the most.
This exciting one-day seminar provides attendees with a unique opportunity to hear in-depth analysis of hot topics and trends concerning global biosimilars while engaging directly with Decision Resources Group analysts.
View the Agenda | Meet our expert speakers
October 30, 2014
In 2023, Medivation/Astellas Pharma’s Xtandi Will Be the Top-Selling Agent in the Prostate Cancer Market Across the United States, Europe, and Japan
Bristol-Myers Squibb/Otsuka’s Abilify is a Preferred Branded Agent for the Treatment of Schizophrenia, According to Surveyed U.S. Psychiatrists and Payers
October 29, 2014
U.S. Physicians and Payers are Generally Positive About the Efficacy of Pfizer’s Xeljanz for Treating RA But They Have Mixed Views About Its Effect on Structural Damage and Safety
The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs
Psoriasis - 2014
Last Updated 28 October 2014Psoriasis is a skin disorder that, depending on its severity and location on... Read More
The Anti-VEGF Era and Beyond in Wet AMD: The Impact of Clinical Attributes and Market Access Status on Current and Future Prescribing Decisions Among Retinal Specialists in the EU5
Treatment for the wet (exudative, neovascular) form of age-related macular degeneration (AMD) in Europe is... Read More
Physician Perspectives on Erythropoiesis-Stimulating Agents, Insulin, and Human Growth Hormone
Nephrologists and endocrinologists in Europe have had the opportunity to use biosimilar erythropoiesis-stimulating... Read More